En español
NIDA

HIV or AIDS

HIV Infection Accelerates Hepatitis C–Related Liver Fibrosis

Study patients with HIV­­–hepatitis C coinfection progressed to successive degrees of severity of liver fibrosis 9 years sooner than those infected with HCV alone. Further findings from the study suggest that suppressing HIV with antiretroviral medications may slow HCV-related liver fibrosis.

World AIDS Day 2013—Addiction Treatment Supports AIDS Treatment

December 1 is World AIDS Day. At NIDA, we always stress the principle that drug abuse treatment is AIDS prevention, because of the close links that exist between drug abuse and the spread of HIV.  Injection drug use alone contributed to more than 7% of new infections in 2011, although the population of people who use drugs by any route who are also HIV-positive is much higher. Drug use goes hand-in-hand with various behaviors besides needle-sharing that place individuals at risk for HIV infection, such as unprotected sex. 

Dr. Marilyn Huestis Q & A: Matching Drug Effects to Drug Concentrations

Dr. Marilyn Huestis of NIDA’s Intramural Research Program talks about conducting research on drug effects with human subjects, developing tests to help law enforcement identify drugged drivers, and an assay to help identify children whose prenatal exposure to anti-HIV drugs may put them at risk for adverse developmental outcomes.

Preventing HIV/AIDS in Vietnam

Credit: PEPFAR VietnamCredit: PEPFAR Vietnam

Study Endorses Onsite HIV Testing Without Risk Reduction Counseling

Patients were more likely to take a rapid HIV test when substance abuse treatment programs offered the test onsite rather than referred for offsite testing. Patients were equally likely to accept and learn their HIV status whether the offer of onsite testing was accompanied by 30 minutes of risk reduction counseling or by 5 minutes of brief information on the testing procedure. Onsite testing accompanied by brief information was cost effective, taking into account the projected lifetime costs of treatment and the gains in health and longevity for detected cases.

Deadline Approaching: U.S.-Mexico Drug Abuse Prevention Research Fellowship

Researchers interested in applying for the NIDA U.S.-Mexico Drug Abuse Prevention Research Fellowship need to submit application materials by April 1, 2013. 

Seek-Test-Treat-Retain To Stop the Spread of HIV

NIDA Director Nora Volkow

Despite the advances in treatment and prevention, roughly 50,000 new HIV infections still occur annually in the Nation. Research, in large part supported by NIDA, has produced a strategy to address this circumstance and break the epidemiological impasse: seek out HIV-infected individuals, particularly those in “hard-to-reach” groups that have minimal contact with the health care system; offer them HIV testing and treatment; and provide support to help them stay in treatment.

Pages

Subscribe to HIV or AIDS